Products/Cancer Cell Models
Boulder Lung Cell Model
General Information
The Boulder Lung Cancer cell model originates from the lung.
Product Family: Boulder Lung Cell Model
Disease Area: Cancer
Tissue Type: Lung
Clinical Diagnosis: Squamous cell carcinoma
Clinical Profile
| Disease Area: | Cancer |
| Tissue Type: | Lung |
| Clinical Diagnosis: | Squamous cell carcinoma |
| Age: | 65-70 |
| Sex: | Male |
| Ethnicity: | Caucasian |
| TNM Stage: | T1aN0MX |
| Grade: | IA |
| Treatment History: | No prior treatment |
| Co-indications: | Abdominal aneurysm, Chronic obstructive pulmonary disease, Gastroesophageal reflux disease, Hiatal hernia, Hypertension, Hyperlipidemia, Motion sickness, Shortness of breath, Transient ischemic attack, Inguinal hernia with surgical repair, Appendectomy, Tonsillectomy, Cataracts with surgical intervention, Surgery of the mandible, Emphysema |
| Medications: | Prednisone, Budesonide and formoterol fumarate, Pantoprazole, Tiotropium, Amlodipine, Chondroitin and glucosamine and methylsulfonylmethane, Albuterol, Pravastatin |
| Country of Collection: | United States |
| Year of Origin: | 2016 |
Characteristics
MORPHOLOGY (2D)
MUTATIONS
|
Gene |
Alteration |
Frequency (%) |
Exon |
Result |
|
APC |
K2524E |
63 |
16 |
Mutated, Variant of Unknown Significance |
|
SMARCA4 |
T1425S |
62 |
31 |
Mutated, Variant of Unknown Significance |
|
ATM |
T1697A |
54 |
34 |
Mutated, Variant of Unknown Significance |
|
TP53 |
R248L |
37 |
7 |
Mutated, Pathogenic |
|
PTPN11 |
R498L |
35 |
13 |
Mutated, Pathogenic |
|
CDKN2A |
R58Q |
33 |
2 |
Mutated, Variant of Unknown Significance |
|
CDKN2A |
L16fs |
29 |
1 |
Mutated, Pathogenic |
|
SMO |
L23dup |
16 |
1 |
Mutated, Presumed Benign |
|
TSC1 |
R204H |
9 |
7 |
Mutated, Variant of Unknown Significance |
BOULDER DRUG RESPONSE
The Boulder Cell Model demonstrates sensitivity to Cisplatin and Etoposide, while showing resistance to Larotrectinib.
BOULDER GROWTH CHARACTERISTICS
The growth curve of Boulder demonstrates consistent and rapid growth. Boulder cells grow continuously for 15+ passages.
Documentation
CELL LINE PROTOCOL
See Passaging Protocol: Lung Cohort for detailed Protocol
STORAGE AND SAFETY
Storage and Stability: Store frozen in liquid nitrogen.
Quality Control: All lots are tested for consistent growth capabilities. See Certificate of Analysis for further details.